KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsBuildingsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLand & ImprovementsLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biogen (BIIB) Other Non-Current Liabilities (2016 - 2025)

Historic Other Non-Current Liabilities for Biogen (BIIB) over the last 17 years, with Q4 2025 value amounting to $748.5 million.

  • Biogen's Other Non-Current Liabilities rose 221.22% to $748.5 million in Q4 2025 from the same period last year, while for Dec 2025 it was $748.5 million, marking a year-over-year increase of 221.22%. This contributed to the annual value of $748.5 million for FY2025, which is 221.22% up from last year.
  • Latest data reveals that Biogen reported Other Non-Current Liabilities of $748.5 million as of Q4 2025, which was up 221.22% from $761.8 million recorded in Q3 2025.
  • Biogen's Other Non-Current Liabilities' 5-year high stood at $1.4 billion during Q1 2021, with a 5-year trough of $556.7 million in Q2 2024.
  • In the last 5 years, Biogen's Other Non-Current Liabilities had a median value of $790.3 million in 2023 and averaged $955.9 million.
  • Per our database at Business Quant, Biogen's Other Non-Current Liabilities plummeted by 3757.62% in 2023 and then surged by 4363.21% in 2025.
  • Quarter analysis of 5 years shows Biogen's Other Non-Current Liabilities stood at $1.3 billion in 2021, then fell by 28.5% to $944.2 million in 2022, then decreased by 17.27% to $781.1 million in 2023, then fell by 6.25% to $732.3 million in 2024, then grew by 2.21% to $748.5 million in 2025.
  • Its last three reported values are $748.5 million in Q4 2025, $761.8 million for Q3 2025, and $799.6 million during Q2 2025.